期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 10, 期 -, 页码 1-12出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758835918762094
关键词
chemotherapy; immune checkpoint inhibitors; immune evasion; immune resistance; non-small cell lung cancer; PD-1 inhibitors; PD-L1; PD-L1 inhibitors; radiotherapy
类别
Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors accelerate tumor progression. Several combination strategies are under evaluation, including the concomitant or sequential evaluation of chemotherapy or radiotherapy with immunotherapy. The current review provides an overview on the molecular rationale for the investigation of combinatorial approaches with chemotherapy or radiotherapy. Moreover, the results of completed clinical studies will be reported.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据